MA38385A1 - Nouvelle composition pour la stéatose hépatique non alcoolique (nafld) - Google Patents
Nouvelle composition pour la stéatose hépatique non alcoolique (nafld)Info
- Publication number
- MA38385A1 MA38385A1 MA38385A MA38385A MA38385A1 MA 38385 A1 MA38385 A1 MA 38385A1 MA 38385 A MA38385 A MA 38385A MA 38385 A MA38385 A MA 38385A MA 38385 A1 MA38385 A1 MA 38385A1
- Authority
- MA
- Morocco
- Prior art keywords
- nafld
- liver disease
- fatty liver
- alcoholic fatty
- new composition
- Prior art date
Links
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 210000004185 liver Anatomy 0.000 abstract 2
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 230000007882 cirrhosis Effects 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 1
- 230000037390 scarring Effects 0.000 abstract 1
- 230000007863 steatosis Effects 0.000 abstract 1
- 231100000240 steatosis hepatitis Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1468MU2013 IN2013MU01468A (cg-RX-API-DMAC10.html) | 2013-04-22 | 2013-06-25 | |
| PCT/IN2013/000391 WO2014174524A1 (en) | 2013-04-22 | 2013-06-25 | A novel composition for nonalcoholic fatty liver disease (nafld) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA38385A1 true MA38385A1 (fr) | 2017-09-29 |
Family
ID=49253372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA38385A MA38385A1 (fr) | 2013-04-22 | 2013-06-25 | Nouvelle composition pour la stéatose hépatique non alcoolique (nafld) |
Country Status (21)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3009136A1 (en) | 2011-01-31 | 2016-04-20 | Cadila Healthcare Limited | Treatment for lipodystrophy |
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| UA114360C2 (uk) | 2013-04-22 | 2017-05-25 | Каділа Хелткере Лімітед | Спосіб лікування та/або зменшення інтенсивності неалкогольної жирової хвороби печінки (нжхп) |
| US20160107989A1 (en) | 2013-05-30 | 2016-04-21 | Cadila Healthcare Limited | A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities |
| TW201513857A (zh) | 2013-07-05 | 2015-04-16 | Cadila Healthcare Ltd | 協同性組成物 |
| IN2013MU02470A (cg-RX-API-DMAC10.html) | 2013-07-25 | 2015-06-26 | Cadila Healthcare Ltd | |
| IN2013MU02905A (cg-RX-API-DMAC10.html) | 2013-09-06 | 2015-07-03 | Cadila Healthcare Ltd | |
| WO2017064635A2 (en) | 2015-10-14 | 2017-04-20 | Cadila Healthcare Limited | Pyrrole compound, compositions and process for preparation thereof |
| CN109069503A (zh) * | 2016-04-22 | 2018-12-21 | 景凯生物科技股份有限公司 | 纳美芬(nalmefene)、纳曲酮(naltrexone)或其衍生物在治疗(非)酒精性脂肪肝炎(nash)或非酒精性脂肪性肝病(nafld)的应用 |
| EP3551180B1 (en) * | 2016-12-09 | 2021-09-29 | Cadila Healthcare Limited | Treatment for primary biliary cholangitis |
| ES2982801T3 (es) | 2017-03-28 | 2024-10-17 | Gilead Sciences Inc | Combinaciones terapéuticas para el tratamiento de las enfermedades hepáticas |
| GB201710229D0 (en) * | 2017-06-27 | 2017-08-09 | Tdeltas Ltd | Compounds for new use |
| CN111182904A (zh) * | 2017-10-06 | 2020-05-19 | 吉利德科学公司 | 包含acc抑制剂的组合治疗 |
| CN109675016A (zh) * | 2017-10-18 | 2019-04-26 | 上海贺普药业股份有限公司 | 非酒精性脂肪性肝病的治疗药物 |
| CN110934866B (zh) * | 2018-09-25 | 2023-12-01 | 深圳微芯生物科技股份有限公司 | 西格列羧及其相关化合物的应用 |
| US12201609B2 (en) * | 2018-12-18 | 2025-01-21 | Zydus Lifesciences Limited | Saroglitazar for the treatment of hepatocellular carcinoma |
| WO2020165782A1 (en) * | 2019-02-13 | 2020-08-20 | Cadila Healthcare Limited | Treatment for polycystic ovarian syndrome (pcos) |
| WO2022128870A1 (en) * | 2020-12-18 | 2022-06-23 | Société des Produits Nestlé S.A. | Compositions and methods using at least one glycine or derivative thereof and/or at least one n-acetylcysteine or derivative thereof, and at least one thymol and/or carvacrol |
| US20220378786A1 (en) * | 2021-05-21 | 2022-12-01 | HepQuant, LLC | Methods of defining functional change and slowing progression in chronic liver disease |
| WO2025238663A1 (en) * | 2024-05-16 | 2025-11-20 | Zydus Lifesciences Limited | Saroglitazar for the treatment of alcoholic liver diseases |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4231938A (en) | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
| US4444784A (en) | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
| MX7065E (es) | 1980-06-06 | 1987-04-10 | Sankyo Co | Un procedimiento microbiologico para preparar derivados de ml-236b |
| US5354772A (en) | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
| FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| US5089514A (en) | 1990-06-14 | 1992-02-18 | Pfizer Inc. | 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents |
| SK695A3 (en) | 1992-07-03 | 1995-07-11 | Smithkline Beecham Plc | Heterocyclic compounds method of their production and using |
| GB9225386D0 (en) | 1992-12-04 | 1993-01-27 | Smithkline Beecham Plc | Novel compounds |
| US5387613A (en) | 1993-07-23 | 1995-02-07 | Ribogene, Inc. | Treatment of tachyarrhythmias of supraventricular origin |
| GB9326171D0 (en) | 1993-12-22 | 1994-02-23 | Smithkline Beecham Plc | Novel compounds |
| WO1996004261A1 (en) | 1994-07-29 | 1996-02-15 | Smithkline Beecham Plc | Benzoxazoles and pryridine derivatives useful in the treatment of the type ii diabetes |
| US6075140A (en) | 1995-04-28 | 2000-06-13 | Daiichi Pharmaceutical Co., Ltd. | Pentacyclic compound |
| GB9600464D0 (en) | 1996-01-09 | 1996-03-13 | Smithkline Beecham Plc | Novel method |
| GB9606805D0 (en) | 1996-03-30 | 1996-06-05 | Glaxo Wellcome Inc | Medicaments |
| WO1999019313A1 (en) | 1997-10-27 | 1999-04-22 | Dr. Reddy's Research Foundation | Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them |
| EP1124807A1 (en) | 1997-10-27 | 2001-08-22 | Dr. Reddy's Research Foundation | Novel heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them |
| CN1208326C (zh) | 1998-04-23 | 2005-06-29 | 雷迪实验室有限公司 | 杂环化合物及其在医药方面的应用、其制备方法及含有它们的药物组合物 |
| JP2002507543A (ja) | 1998-05-27 | 2002-03-12 | ドクター・レディーズ・リサーチ・ファウンデーション | 二環系化合物、その製造方法およびそれらを含有する薬学的組成物 |
| WO2000023445A1 (en) | 1998-10-21 | 2000-04-27 | Novo Nordisk A/S | New compounds, their preparation and use |
| EP1123269A1 (en) | 1998-10-21 | 2001-08-16 | Novo Nordisk A/S | New compounds, their preparation and use |
| EP1123297A1 (en) | 1998-10-21 | 2001-08-16 | Novo Nordisk A/S | New compounds, their preparation and use |
| CO5150173A1 (es) | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
| ES2449194T3 (es) | 2000-01-19 | 2014-03-18 | Cadila Healthcare Limited | Compuestos que tienen actividades hipolipidémica e hipocolesterolémica, procedimiento para su preparación y composiciones farmacéuticas que los contienen |
| US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
| WO2002024625A2 (en) | 2000-09-22 | 2002-03-28 | Dr. Reddy's Research Foundation | Process for the preparation of 3-aryl-2-hydroxy propanoic acid derivatives |
| UA74912C2 (en) | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
| US6987123B2 (en) | 2001-07-26 | 2006-01-17 | Cadila Healthcare Limited | Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine |
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| JP4261546B2 (ja) | 2003-09-26 | 2009-04-30 | 三菱レイヨン株式会社 | 電気泳動装置および電気泳動法 |
| CN102079743B (zh) | 2004-03-15 | 2020-08-25 | 武田药品工业株式会社 | 二肽基肽酶抑制剂 |
| EP2096170B1 (en) * | 2005-09-19 | 2011-08-10 | Isis Pharmaceuticals, Inc. | Modulation of glucagon receptor expression |
| WO2008036638A2 (en) * | 2006-09-18 | 2008-03-27 | Alnylam Pharmaceuticals, Inc. | Rnai modulation of scap and therapeutic uses thereof |
| JP2008184429A (ja) * | 2007-01-30 | 2008-08-14 | Japan Health Science Foundation | 肝臓トリグリセリド濃度低下剤 |
| ES2441665T3 (es) | 2009-11-26 | 2014-02-05 | Genfit | Utilización de derivados de 1,3-difenilprop-2-en-1-ona para tratar trastornos hepáticos |
| MX2013004123A (es) | 2010-10-12 | 2013-12-16 | Univ Johns Hopkins | Composiciones antitusigenas que comprenden memantina. |
| EP3009136A1 (en) * | 2011-01-31 | 2016-04-20 | Cadila Healthcare Limited | Treatment for lipodystrophy |
| UA114360C2 (uk) | 2013-04-22 | 2017-05-25 | Каділа Хелткере Лімітед | Спосіб лікування та/або зменшення інтенсивності неалкогольної жирової хвороби печінки (нжхп) |
| US20160107989A1 (en) | 2013-05-30 | 2016-04-21 | Cadila Healthcare Limited | A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities |
| TW201513857A (zh) | 2013-07-05 | 2015-04-16 | Cadila Healthcare Ltd | 協同性組成物 |
| IN2013MU02470A (cg-RX-API-DMAC10.html) | 2013-07-25 | 2015-06-26 | Cadila Healthcare Ltd | |
| US9951009B2 (en) | 2013-08-29 | 2018-04-24 | Cadila Healthcare Limited | Polymorphic form of pyrrole derivative and intermediate thereof |
| IN2013MU02905A (cg-RX-API-DMAC10.html) | 2013-09-06 | 2015-07-03 | Cadila Healthcare Ltd |
-
2013
- 2013-06-25 UA UAA201509744A patent/UA114360C2/uk unknown
- 2013-06-25 WO PCT/IN2013/000391 patent/WO2014174524A1/en not_active Ceased
- 2013-06-25 HK HK16103017.5A patent/HK1214968A1/zh unknown
- 2013-06-25 AP AP2015008674A patent/AP2015008674A0/xx unknown
- 2013-06-25 JP JP2016505927A patent/JP6246895B2/ja active Active
- 2013-06-25 US US14/782,609 patent/US20160166539A1/en not_active Abandoned
- 2013-06-25 MY MYPI2015002026A patent/MY180160A/en unknown
- 2013-06-25 KR KR1020157024370A patent/KR101617812B1/ko active Active
- 2013-06-25 SG SG11201506218UA patent/SG11201506218UA/en unknown
- 2013-06-25 GE GEAP201313941A patent/GEP201706663B/en unknown
- 2013-06-25 MA MA38385A patent/MA38385A1/fr unknown
- 2013-06-25 IN IN1468MU2013 patent/IN2013MU01468A/en unknown
- 2013-06-25 EP EP13767126.9A patent/EP2988736A1/en not_active Withdrawn
- 2013-06-25 CA CA2900435A patent/CA2900435C/en not_active Expired - Fee Related
- 2013-06-25 BR BR112015020600A patent/BR112015020600A2/pt not_active IP Right Cessation
- 2013-06-25 CN CN201380075905.9A patent/CN105377246B/zh active Active
- 2013-06-25 EA EA201592020A patent/EA201592020A1/ru unknown
- 2013-06-25 AU AU2013387996A patent/AU2013387996B2/en not_active Ceased
- 2013-06-25 MX MX2015010769A patent/MX346943B/es active IP Right Grant
-
2015
- 2015-07-28 IL IL240183A patent/IL240183A/en not_active IP Right Cessation
- 2015-08-14 PH PH12015501795A patent/PH12015501795A1/en unknown
-
2016
- 2016-08-11 IL IL247231A patent/IL247231A/en not_active IP Right Cessation
- 2016-11-04 US US15/343,859 patent/US9814697B2/en active Active
-
2017
- 2017-11-02 US US15/801,738 patent/US20180185330A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016515608A (ja) | 2016-05-30 |
| IL247231A (en) | 2017-03-30 |
| MX346943B (es) | 2017-04-06 |
| JP6246895B2 (ja) | 2017-12-13 |
| EA201592020A1 (ru) | 2016-05-31 |
| WO2014174524A1 (en) | 2014-10-30 |
| AU2013387996B2 (en) | 2015-12-10 |
| US20160166539A1 (en) | 2016-06-16 |
| UA114360C2 (uk) | 2017-05-25 |
| IL240183A (en) | 2016-08-31 |
| BR112015020600A2 (pt) | 2017-07-18 |
| IL240183A0 (en) | 2015-09-24 |
| AU2013387996A1 (en) | 2015-09-24 |
| PH12015501795A1 (en) | 2015-11-09 |
| GEP201706663B (en) | 2017-05-10 |
| US20180185330A1 (en) | 2018-07-05 |
| US20170087127A1 (en) | 2017-03-30 |
| CN105377246A (zh) | 2016-03-02 |
| CA2900435C (en) | 2017-02-14 |
| KR101617812B1 (ko) | 2016-05-03 |
| US9814697B2 (en) | 2017-11-14 |
| HK1214968A1 (zh) | 2016-08-12 |
| AP2015008674A0 (en) | 2015-08-31 |
| EP2988736A1 (en) | 2016-03-02 |
| WO2014174524A8 (en) | 2015-10-01 |
| CA2900435A1 (en) | 2014-10-30 |
| MX2015010769A (es) | 2015-11-26 |
| SG11201506218UA (en) | 2015-09-29 |
| KR20150118990A (ko) | 2015-10-23 |
| CN105377246B (zh) | 2018-03-20 |
| IN2013MU01468A (cg-RX-API-DMAC10.html) | 2015-04-17 |
| MY180160A (en) | 2020-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA38227A1 (fr) | Nouveaux composés bicycliques et leur utilisation en tant qu'agents antibactériens et inhibiteurs de ?-lactamase | |
| MA58181B1 (fr) | Composés tricycliques substitués | |
| TN2013000393A1 (fr) | Derives de la pyrazolospirocetone pour une utilisation comme inhibiteurs de l'acetyl-coa carboxylase | |
| WO2019007696A1 (en) | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | |
| MA37762B1 (fr) | Composés n-aryltriazole utilisés comme antagonistes de lpar | |
| MA44474B1 (fr) | Inhibiteurs de la ferroportine | |
| MA42678B1 (fr) | Nouveaux analogues nucléosidiques substitués à cycle aromatique bicyclique 6-6 pour une utilisation en tant qu'inhibiteurs de prmt5 | |
| MA50391B1 (fr) | Composés d' imidazo[4,5-b]pyridine et compositions pharmaceutiques les contenant destinés à traiter les troubles inflammatoires | |
| MA35128B1 (fr) | Nouveaux dérivés d'imidazole utiles pour le traitement de l'arthrite | |
| MA37866B1 (fr) | Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur | |
| MA38333A1 (fr) | Composés d'azabenzimidazole en tant qu'inhibiteurs d'isozymes pde4 pour le traitement de troubles du snc et d'autres affections | |
| MA37929A1 (fr) | Composés bis(fluoroalkyl) -1,4-benzodiazépinones en tant qu'inhibiteurs de notch | |
| PH12015501795A1 (en) | A novel composition for nonalcoholic fatty liver disease (nafld) | |
| BR112013028095A2 (pt) | inibidores de csf-1r para o tratamento de tumores cerebrais | |
| BR112013021566A2 (pt) | composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula | |
| MA37888A1 (fr) | Composition pharmaceutique enrobée contenant du régorafenib | |
| MA37891B1 (fr) | Alcoxypyrazoles comme activateurs de guanylate cyclase soluble | |
| MA37439A1 (fr) | Inhibiteurs de dgat1 à ponts éthers cycliques pour le traitement de troubles medies par l'acyle coa-diacylglycerol transferase 1 (dgat1). | |
| MA37765A1 (fr) | Composés de pyrazole substitués utilisés comme antagonistes de lpar | |
| MA38935B1 (fr) | Dérivés de diazacarbazole à titre de ligands tau-pet | |
| MA39972A (fr) | Composés et compositions d'induction de la chondrogenèse | |
| MA34917B1 (fr) | Dérivés substitués de l'acide 3-hétéroaroylamino-propionique et leur utilisation comme composés pharmaceutiques | |
| MA35363B1 (fr) | Utilisation d'un composé organisation dans le traitement du syndrome de noonan | |
| MA38410A1 (fr) | Composés d'azétidinyloxyphénylpyrrolidine | |
| MA43913B1 (fr) | Modulateurs allostériques positifs du récepteur m1 muscarinique |